Transarterial Chemoembolization of Child-A hepatocellular carcinoma: Drug-eluting bead TACE (DEB TACE) vs. TACE with Cisplatin/Lipiodol (cTACE)

Philipp Wiggermann\textsuperscript{1}\textsuperscript{AM}, Dominik Sieron\textsuperscript{1,2}\textsuperscript{FD}, Christiane Brosche\textsuperscript{1}\textsuperscript{BF}, Thomas Brauer\textsuperscript{1}\textsuperscript{BF}, Fabian Scheer\textsuperscript{1}\textsuperscript{F}, Ivan Platzek\textsuperscript{1}\textsuperscript{DF}, Wojciech Wawrzyn\textsuperscript{2}\textsuperscript{DF}, Christian Stroszczynski\textsuperscript{1}\textsuperscript{ADEF}

\textsuperscript{1}Department of Radiology, Dresden University of Technology, Dresden, Germany
\textsuperscript{2}Department of Radiology, District Hospital of Orthopaedics and Trauma Surgery, Piekary Slaskie, Poland

Source of support: There where no source(s) of support in the form of grants, equipment, drugs etc.

Summary

Background:

This study is an outcome evaluation of the Drug-Eluting-Beach-Chemoembolization (DEB TACE) compared to conventional TACE (cTACE) with Cisplatin and Lipiodol in patients with hepatocellular carcinoma (HCC) and Child-Pugh A Cirrhosis.

Material/Methods:

A comparison of interventional therapy with either cTACE or DEB-TACE of 22 patients each with unresectable HCC and Child-Pugh A Cirrhosis was carried out. A comparison of therapy-associated complications, tumour response rates and mean survival was performed. Tumour response was evaluated in accordance with the European Association for the Study of the Liver (EASL) response criteria by two radiologists in consensus reading.

Results:

The choice of TACE procedure (DEB TACE/cTACE) had no significant impact on therapy-associated complications. Objective Response (OR, complete response + partial response) for DEB-TACE was 22.7%; a further 68.2% was stable disease (SD). The respective response rates for the cTACE were OR 22.7 and SD 31.8%. Thus disease control was not significantly increased for DEB-TACE (p=0.066). After DEB-TACE mean survival was significantly prolonged with 651±76 days vs. 414±43 days for cTACE (p=0.01).

Conclusions:

Associated with a similar safety profile and an at least comparable tumour response, the DEB-TACE is a method of treatment for HCC that has the potential to improve mean survival compared to cTACE with Cisplatin/Lipiodol.

key words: HCC • TACE • Drug Eluting Bead • Cisplatin • Epirubicin

Full-text PDF: http://www.medscimonit.com/fulltxt.php?ICID=881714

Word count: 2479
Tables: 2
Figures: 7
References: 25

Author’s address: Philipp Wiggermann, Department of Radiology, Dresden University of Technology, Fetscherstr. 74, 01307 Dresden, Germany, e-mail: openphw@googlemail.com
BACKGROUND

Hepatocellular carcinoma (HCC) is currently the fifth most frequent tumour worldwide. HCC is in third place in the statistics for tumour-associated deaths. The annual incidence of new cases is about 500,000 persons, and about 80% of these patients die in the first year of diagnosis [1,2].

The great majority of HCC patients are not candidates for liver resection because they have advanced disease with extensive tumour growth, greatly impaired functional reserve of the cirrhotic liver and/or existing portal hypertension, possibly with concomitant thrombosis of the portal vein [1,3–6].

Material and Methods

Patient characteristics

In the period 2003 to 2008, 74 consecutive patients with histologically confirmed HCC were treated by TACE in our institution. 44 of these patients were included in this retrospective evaluation. All patients with an advanced stage of liver cirrhosis (Child-Pugh B or C) were excluded, as advanced hepatic failure is the critical prognostic factor for survival in these patients [16,17]. Moreover, patients with embolization alone (TAE), combined therapy (e.g. RFA+TACE), and patients who had partial liver resection or liver transplantation after TACE were not included in this study. Patients who had both cTACE and DEB-TACE were not included either. 37 men and 7 women with HCC at an advanced inoperable stage were included (Table 1). The average age at the time of histological confirmation (first diagnosis) of the HCC was 69.02±8.11 years (min 45.6/max 84.7). All of the patients had Child-A cirrhosis. 13 cases of cirrhosis were of toxic nutritional aetiology (ethanol) and 5 were due to infection. The remaining 26 patients had cryptogenic cirrhosis. The patients had either one or more administrations of cTACE (n=22), or were given one or more DEB-TACE treatments (n=22); 89 sessions in total (Figure 1).

Indication

The therapeutic procedure was decided in an interdisciplinary tumour conference together with the visceral surgeons and medical oncologists. Curability by surgical resection or radiological intervention (RFA or PEI) was first ruled out according to the treatment algorithm of the Barcelona Clinic Liver Cancer (BCLC) classification [18].

TACE exclusion criteria

The exclusion criteria for TACE were tumour involving >75% of the liver, diffuse, non-focal HCC, extrahepatic manifestations, advanced liver cirrhosis of Child-Pugh stage B or C, severe cardiopulmonary comorbidity and known hypersensitivity to lipiodol, epirubicin or cisplatin.

Chemoembolization protocol

A transfemoral access was chosen in all cases. After local anaesthesia of the skin and subcutaneous tissue (10–20 ml prilocaine hydrochloride), a 5F standard catheter was placed through a 5F introducer in the initial treatment session. Angiography of the upper abdominal vessels was performed first to determine the arterial supply of the liver by means of automated injection of contrast agent. Apart from selective imaging of the coeliac trunk, the superior mesenteric artery was examined separately in order to rule out normal variants of the hepatic blood supply. In the event of a normal supply, the common hepatic artery was cannulated over a hydrophilic guide wire and the catheter was placed in the right or left hepatic artery according to the tumour location. Supersелективная embolization only of the segmental or subsegmental arteries supplying the tumour was performed by means of a microcathether (Progreat 2.7 F; Terumo or Tracker 2.4 F; Boston Scientific). In cTACE an emulsion consisting of 20 mg cisplatin and 20 ml lipiodol followed by particle embolization (Contour SE; Boston Scientific) was delivered at each session. In DEB-TACE 50 mg epirubicin coupled with 2 ml DC Beads (1 vial of 300–500 µm DC Beads) was given at each session. Particle embolization (Contour SE; Boston Scientific) was performed in addition where necessary. The treatment was concluded after stasis or reflux occurred in the corresponding vascular segment (second- or third-order branches of the right or left hepatic artery) (Figure 2). The patients were admitted to a ward for monitoring and were discharged the next day if asymptomatic. Nausea, pain or fever subsequently were treated symptomatically depending on their severity, e.g. with Navoban 5–15 mg i.v., analgesics (e.g. Metamizole i. v. or drops) and antipyretic agents (e.g. Paracetamol tablets 500–1000 mg).

The decision for re-treatment was based on the absence of TACE contraindications and the sequential TACE procedures were performed within 2 weeks after documentation of response. In case of complete response or partial...
response the patients were first re-evaluated in the inter
disciplinary tumour conference to assess curability by sur-
gical resection or radiological intervention (RFA or PEI).
Diminishing hepatic functional reserves as well as a marked
reduction of general health status were the most common
causes to stop sequential TACE procedures.

CT/MRI documentation protocol

Pre-treatment CT or MRI scans were used as a basis for docu-
menting the initial findings (maximum of 4 weeks old). The
minimum radiological requirement required for discussion
in the tumour conference was either a biphasic contrast-en-
hanced CT or MRI with the specific hepatic contrast agent
Gd-EOB-DTPA. In follow-up, the local response to therapy was
documented 6–8 weeks after TACE using the same modality
(Figures 3, 4). The response to therapy was assessed accord-
according to the criteria of the European Association for the Study
of the Liver (EASL) by two experienced abdominal radiolo-
gists (more than 5 years experience) in consensus. The basis
for this was comparison of the initial finding with the last doc-
umented examination of the patient. Thus, the therapeutic in-
fluence of the two TACE therapies was compared in the long-
term course (mean 8.09 months, sd 6.6 months) of the HCC.

Complications

Complications that occurred in association with the TACE
treatment were recorded based on the guidelines of the
Society for Interventional Radiology [19]. Minor compi-
lcations correspond to negative effects that are associated
with the intervention and either require no consequence
and therapy or else result only in nominal therapy without
negative consequences including overnight hospitalisation.
Major complications are hospitalisation > 24 h, greater ther-
apy and unplanned added costs in treatment, permanent
persisting sequelae and death of the patient.

Data collection and statistics

The data for our study were recorded by analysis of the radio-
logical databases (reports, images), by viewing the patient’s file
and by personal contact with patients, relatives and treating
doctors. If necessary, enquiries were made in various institu-
tions (date of death, cause of death). The primary endpoint
of the analysis was the interval from the first TACE until the
patient’s death. Secondary endpoints were the local response
to therapy and the rate of therapy-associated complications.

| Table 1. | Patients demographics: comparison of clinical features of patients: cTACE/DEB TACE. |
|----------|---------------------------------------------------------------|
|          | cTACE (n=22) | DEB TACE (n=22) | p           |
| Age mean ±SD (min-max) | 67.72±9.02 (45.6–84.3) | 70.32±7.06 (55.2–84.7) | 0.549** |
| Sex       |               |                   | 0.68***     |
| Male      | 19 (86.4%)   | 18 (82%)          |             |
| Female    | 3 (13.6%)    | 4 (18%)           |             |
| Aetiology |               |                   | 0.806***    |
| Alcohol alone | 7 (32%)   | 2 (9%)            |             |
| Hepatitis | 3 (14%)      | 6 (27%)           |             |
| Other and mixed | 12 (54%) | 14 (64%)       |             |
| Clinical features | |                   |             |
| Child-Pugh A | 22 (100%) | 22 (100%)      |             |
| BCLC (A/B/C)* | 4,15,2    | 1,17,3           | 0.547***    |
| Tumour diameter mean ±SD (cm) | 6.98±3.81 | 7.44±3.37    | 0.496** |
| Unifocal/Multifocal tumour | 9 (41%)/13 (59%) | 12 (55%)/10 (44%) | 0.365*** |

* BCLC classification [15]; ** Mann-Whitney-U; *** Pearson’s chi-square test / Fisher’s exact test.
Statistical analysis was performed with SPSS (version 15.0 for Windows). The survival rate, calculated from the time of the first intervention until death, was determined according to the Kaplan-Meier method. The univariate log-rank test was used to assess statistically significant differences between the survival curves. The statistical significance of quantitative data was determined using the parameter-free Wilcoxon-Mann-Whitney test. The qualitative variables were tested for significance with the Pearson chi square test and where necessary with Fisher’s exact test. A p<0.05 was regarded as statistically significant.

**RESULTS**

A total of 44 patients with HCC at an advanced inoperable disease stage were included. There were no significant differences between the two treatment groups with regard to demographic data, tumour burden and health status (Table 1). The average lesion diameter was 6.98 ± 3.81 cm (2.3 to 16.0) in the cTACE group and 7.44±3.37 cm (3.9 to 16.2) in the DEB-TACE group. 13 of 22 patients in the cTACE group had multifocal HCC and the proportion in the DEB-TACE group was 10 out of 22.

**Therapy-induced side effects**

7 major complications and 17 minor complications occurred in total with 89 TACE treatments (Table 2). Minor complications belonged to the „post-embolization syndrome“, which is expressed by fever, fatigue, abdominal pain and nausea. 7 (16%) cases of minor complications were recorded for cTACE.
In the DEB-TACE group, 6 major complications occurred (including 2 liver abscesses) compared with 1 major complication in the cTACE group (Table 2). A statistically significant difference with regard to therapy-associated complications was not found although the p-value of 0.06 for the major complications is indicative of a possibly increased risk with DEB-TACE treatment.

**Tumour response rates according to EASL**

After an average of 8 months, complete remission was achieved in 13.6% vs. 0% of patients, partial remission in 9.1% vs. 22.7% of patients and stable disease in 68.2% vs. 45.5 of patients in the DEB-TACE and cTACE arms respectively. Progression of the HCC was seen in 9.1% vs. 31.8% of patients (Figure 5). This results in an objective response (OR; complete remission + partial remission) of 22.7% vs. 22.7% (DEB-TACE vs. cTACE); this difference is not significant. Disease control (DC; objective response + stable disease) was achieved in 90.9% and 68.2% respectively (Figure 6). While there were no differences with regard to OR, there was a trend to better results in the DEB-TACE group on average with regard to DC (p=0.066).

**Survival rates**

The survival in the cTACE group was 414±43 days on average (95% CI; 329–499) and 651±76 days (95% CI; 502–800) in the DEB-TACE group. The influence of the form of therapy on the survival rate was significant in the log-rank test (p=0.01). The corresponding one-year survival probability was 55% in the cTACE group and 70% in the DEB-TACE group (Figure 7).
TACE currently represents the first-line therapy of inoperable HCC [8]. Although this is an established therapy, there is still disagreement on the best combination of the anti-tumour drug to be administered, the embolic agents, the doses to be given and the frequency of treatment. The local response rates published in the literature and survival rates vary markedly. This study presents the results in patients of a single university centre with inoperable HCC and Child-Pugh stage A hepatic cirrhosis, who were treated with palliative intent with cTACE or DEB-TACE. DC beads (Biocompatibles UK Ltd.) are a new drug delivery and embolization system for embolization of vessels supplying hypervascularised malignant tumours enabling simultaneous administration of a local, controlled, sustained dose of a chemotherapeutic agent to the tumour [14,15]. In preclinical and clinical studies, prolonged and greater persistence of the chemotherapeutic agent in the tumour was confirmed [14,15,20,21]. At the same time, the systemic effect of the administered drugs is less because of lower plasma levels [22]. Lammer et al. showed a trend to higher response rates with DEB-TACE compared with cTACE with doxorubicin and lipiodol in the only prospective multicentre study so far. In the majority of published studies on DEB-TACE, doxorubicin was used as chemotherapeutic agent. In this study, the DC beads were loaded with epirubicin. The objective of this study was to compare the clinical results of this new embolization method with the results of conventional TACE with cisplatin and lipiodol. Even though this study was a comparison of historical groups, there was still clear evidence of a prolongation of the average survival; with a difference of 237 days in favour of DEB-TACE, a significant survival advantage was shown for the first time in this study for DEB-TACE compared with cTACE (p=0.01). This might be due to the markedly lower rate of progression in the DEB group (9.1% for DEB-TACE vs. 31.8% for cTACE, p=0.064). The objective response rates for DEB-TACE published hitherto are between 44 and 82% [20,21,23,24]. It must be borne in mind that the previous data refer to the 6-month OR. In contrast, the time of follow-up evaluation of the therapy in this study was 8.1 months on average (sd 6.6 months). This might partially explain the lower OR of 22.7% after DEB-TACE for palliation, when follow-up was prolonged by one third. There is another important methodological difference compared to previous publications, the use of epirubicin instead of doxorubicin as the agent to load the drug-eluting beads. Thus the efficacy of epirubicin in DEB-TACE might be lower than the one of doxorubicin leading to a lower OR. As previously in the PRECISION V study [25], which evaluated the success of therapy after 6 months, a significantly higher OR in the DEB-TACE group compared with cTACE was not confirmed in this study with the longer follow-up. However, a trend to better disease control was apparent (90.9% vs. 68.2% DEB-TACE vs. cTACE, p=0.065). Analysis of the side effect profiles did not result in any statistically significant differences, but our data appear to indicate an increased side effect risk with DEB-TACE, particularly with regard to serious complications such as liver abscess. This might be due to the greater greater embolic effect of DEB-TACE in hepatic tissue. The limitations of the present study are its retrospective character and the limited number of patients. Because of the historical patient groups and retrospective study, it is likely that the framework conditions differed so that, for example, technical progress and increasing operator experience led to more frequent achievement of superselective catheter positioning, which might have favourably influenced the results in the DEB-TACE group. Since other factors might have influenced patient survival besides the selected treatment options, the results of this study must be appraised with caution. However, we believe that it would be useful to investigate transarterial drug-eluting bead chemobilization in larger groups of patients in further studies.

**Conclusions**

In conclusion, the DEB TACE of inoperable HCC represents an effective new treatment option. It is associated with
a similar safety profile and at least comparable tumour response rates compared to the cTACE. At the same time it does seem that DEB TACE has the potential to prolong the patients’ average survival compared to cTACE.

References:

1. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet, 2003; 362: 1907–17
2. Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 2009; 27: 1485–91
3. Bolondi L, Sofia S, Stringo S et al: Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut, 2001; 48: 251–59
4. Georgiades CS, Hong K, D’Angelo M, Geschwind JF: Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol, 2005; 16: 1653–59
5. Geschwind JF: Chemoembolization for hepatocellular carcinoma: where does the truth lie? J Vasc Interv Radiol, 2002; 13: 991–94
6. Witczak-Malinowska K, Zadrozny D, Studniarek M et al: Preliminary assessment of utility of radiofrequency ablation technique in treatment of primary hepatocellular carcinoma (HCC) in patients with hepatic cirrhosis. Med Sci Monit, 2003; 9(Suppl.5): 68–72
7. Mazzaferro V, Regalia E, Doci R et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996; 334: 693–99
8. Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology, 2002; 35: 1164–71
9. Llovet JM, Real MI, Montana X et al: Arterial embolisation or chemoembolisation for hepatocellular carcinoma: a randomised controlled trial. Lancet, 2002; 359: 1734–39
10. Lo CM, Ngan H, Tso WK et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology, 2002; 35: 1164–71
11. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology, 2003; 37: 429–42
12. Marelli L, Sigliano R, Triantos C et al: Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Interv Radiol, 2007; 30: 6–25
13. Spaht L, Becker C, Pugin J et al: Acute portal hemodynamics and cytokine changes following selective transarterial chemoembolization in patients with cirrhosis and hepatocellular carcinoma. Med Sci Monit, 2003; 9(9): CR385–88
14. Lewis AL, Gonzalez MV, Leppard SW et al: Doxorubicin eluting beads – I: effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med, 2007; 18: 1691–99
15. Lewis AL, Gonzalez MV, Lloyd AW et al: DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol, 2006; 17: 335–42
16. D’Amico G, Garcia-Tsao G, Pagliaro L: Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol, 2006; 44: 217–31
17. Xu J, Shi J, Wang YP et al: Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis. Med Sci Monit, 2009; 15(6): CR274–79
18. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis, 1999; 19: 329–38
19. Sacks D, McClenny TE, Cardella JF, Lewis CA: Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol, 2003; 14: S199–202
20. Varela M, Real MI, Burrel M et al: Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol, 2007; 46: 474–81
21. Poon RT, Tso WK, Pang RW et al: A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intraarterial drug-eluting bead. Clin Gastroenterol Hepatol, 2007; 5: 1108–13
22. Hong K, Khwaja A, Liapi E et al: New intraarterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res, 2006; 12: 2563–67
23. Kettenbach J, Stadler A, Katzler IV et al: Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Interv Radiol, 2008; 31: 51–66
24. Malagari K, Chatzimichael K, Aleksopoulou E et al: Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Interv Radiol, 2008; 31: 269–80
25. Lammer J, Malagari K, Vogl T et al: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol, 2010; 33: 41–52